Focused On-demand Library for Pleckstrin homology domain-containing family M member 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9Y4G2

UPID:
PKHM1_HUMAN

ALTERNATIVE NAMES:
162 kDa adapter protein

ALTERNATIVE UPACC:
Q9Y4G2; Q6P2R5; Q8TEL9; Q9NPP5; Q9NYA0

BACKGROUND:
The protein Pleckstrin homology domain-containing family M member 1, alternatively known as the 162 kDa adapter protein, is crucial for the regulation of endolysosomal trafficking. It facilitates the fusion of late endosomes and lysosomes, playing a key role in the degradation pathways of autophagosomes and endocytosed materials. This protein's interaction with cellular GTPases is vital for the maturation of autophagosomes and their fusion with lysosomes, indicating its significant role in cellular homeostasis and defense mechanisms against microbial infections.

THERAPEUTIC SIGNIFICANCE:
The association of Pleckstrin homology domain-containing family M member 1 with osteopetrosis underscores its therapeutic potential. By targeting the mechanisms underlying its role in bone density regulation and endolysosomal trafficking, novel treatment avenues for osteopetrosis and related bone disorders could be developed. Its multifaceted role in biological systems makes it an intriguing subject for scientific inquiry and drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 52 of 8789